Genitourinary Cancer in 2023 and Beyond

Expert perspectives and strategic insights on the latest therapeutic developments and translational research in genitourinary cancer treatment. Topics include clinical decision-making and the extent to which emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.

December 16, 2023
Daniel Petrylak, MD, Yale, Aptitude Health


Daniel Petrylak, MD

Yale University, New Haven, CT, USA

Faculty Members

Oliver Sartor, MD
Mayo Clinic, Rochester, MN, USA

Neeraj Agarwal, MD, FASCO
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

Scott Tagawa, MD, FASCO, FACP
Weill Cornell Medicine, New York, NY, USA

Leonard G. Gomella, MD, FACS
Thomas Jefferson University, Philadelphia, PA, USA

Robert Dreicer, MD, MACP, FASCO
University of Virginia School of Medicine, Charlottesville, VA, USA

Joaquim Bellmunt, MD, PhD
Harvard Medical School, Boston, MA, USA

Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Sample Report

Start discovering the insights

View Report


  • Evolving Paradigms in the Management of CSPC and Nonmetastatic CRPC
  • Current and Emerging Therapies for mCRPC (Excluding Radiopharmaceuticals)
  • Radiopharmaceuticals for Prostate Cancer
  • Early-Stage Bladder Cancer (BCG-Resistant NMIBC; MIBC)
  • Current Paradigms and Future Directions in Metastatic Bladder Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.